Tezepelumab sustains EoE remission, dysphagia relief at 52 weeks
NASHVILLE, Tenn. — Tezepelumab significantly improved histologic remission and dysphagia symptoms at 24 and 52 weeks compared with placebo among individuals with eosinophilic esophagitis, according to a presenter. Thymic stromal lymphopoietin (TSLP), an antibody, is associated with EoE pathogenesis. “Food allergens and
